Weight-Loss Peptide Stacks in Canada: A Research Guide to Multi-Compound Metabolic Protocols

Why weight-loss peptide stacks require their own category#

The search term "weight loss peptide stacks Canada" usually arrives at Northern Compound after a researcher has already read individual guides to semaglutide, tirzepatide, or AOD-9604, and now wants to know whether combining those compounds produces research outcomes beyond what each compound achieves alone. That question is legitimate. It is also easy to overstate.

Energy balance is not a single variable. It is regulated by at least four interacting systems: central appetite circuits in the hypothalamus and brainstem, gastrointestinal transit and nutrient-sensing mechanisms, peripheral adipose tissue lipolysis and lipogenesis, and skeletal-muscle glucose uptake and mitochondrial oxidation. A peptide stack that adds one or more synthetic molecules to this already complex system risks producing effects that are difficult to attribute to any single compound unless the experimental design is explicitly built to disentangle those contributions.

This guide is designed to prevent two common errors. The first is assuming that because two peptides are grouped under "weight loss," they must work better together. The second is assuming that because the evidence is incomplete, no combination is worth studying. The reality is more nuanced: some pairs have orthogonal mechanisms that justify a testable interaction hypothesis, while others overlap so heavily that their combination adds analytical cost without adding epistemic value.

Northern Compound treats all peptides discussed here as research-use-only materials. This guide is not medical advice, not a dosing protocol, not a body-composition regimen, and not a recommendation for personal or therapeutic use. Canadian researchers should operate within the framework of the Food and Drugs Act, institutional ethics approval, and biosafety standards.

The metabolic mechanism landscape: four research categories#

Before evaluating specific combinations, it is worth mapping the four mechanistic categories that define the current weight-loss peptide literature. Each category represents a different physiological system, a different endpoint set, and a different experimental design.

Central appetite suppression and satiety signalling#

This category is dominated by the incretin receptor agonists: semaglutide (GLP-1R), tirzepatide (GLP-1R/GIPR), and retatrutide (GLP-1R/GIPR/GCGR). These compounds act primarily on hypothalamic melanocortin circuits, brainstem satiety centres, and vagal afferent signalling to reduce food intake. The GLP-1 revolution has produced the largest Phase 3 weight-loss trials in history, with retatrutide's TRIUMPH-2 data showing approximately 24.2% mean body-weight reduction at 48 weeks in the 12 mg arm.

The central appetite category also includes cagrilintide, an amylin receptor agonist that acts on area postrema and hypothalamic arcuate nucleus neurons through a pathway that is distinct from GLP-1 receptor signalling. Amylin is co-secreted with insulin from pancreatic beta cells and has been described as a partner hormone to insulin in postprandial glucose and appetite regulation.

Gastrointestinal transit and nutrient absorption#

GLP-1 receptor agonists slow gastric emptying and delay intestinal transit, which reduces the rate of nutrient absorption and contributes to postprandial satiety. This effect is dose-dependent and can be measured directly with gastric scintigraphy or indirectly with continuous glucose monitoring. Tirzepatide's dual agonism produces more pronounced gastrointestinal slowing than semaglutide at comparable weight-loss doses, which may explain some of the differences in glycaemic control and tolerability between the two compounds.

Peripheral lipolysis and adipose tissue remodelling#

This category is represented by AOD-9604, a 15-amino-acid fragment of human growth hormone corresponding to residues 176-191. Unlike full-length hGH, AOD-9604 does not elevate IGF-1, bind to the growth hormone receptor, or stimulate generalized growth. Its proposed mechanism is beta-3 adrenergic receptor activation in adipocytes, leading to increased lipolysis, reduced lipogenesis, and preferential fat-mass reduction. The literature is older and smaller than the incretin literature, but the mechanism is distinct enough to make AOD-9604 an interesting adjuvant in combination research.

Mitochondrial metabolic flux and insulin sensitivity#

This category is represented by MOTS-c, a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. MOTS-c activates AMP-activated protein kinase (AMPK) and has been described as an exercise mimetic in animal models. It does not suppress appetite directly; instead, it improves skeletal-muscle glucose uptake, enhances fatty-acid oxidation, and ameliorates insulin resistance in high-fat-diet models. Its relevance to weight-loss stack design is metabolic rather than anorectic.

Why the four categories matter for stack design#

A stack that combines two peptides from the same category risks additive receptor occupancy without mechanistic insight. A stack that combines peptides from different categories has a stronger rationale, because it asks whether two independent metabolic systems can be modulated simultaneously to produce an outcome that neither system produces alone. The question is not "more is better." The question is "do these two pathways interact in a way that produces a measurable, interpretable effect?"

The semaglutide + cagrilintide combination (CagriSema)#

Mechanistic rationale#

The most defensible weight-loss stack in the current clinical literature is the combination of semaglutide and cagrilintide, developed under the name CagriSema by Novo Nordisk. The rationale rests on receptor complementarity. Semaglutide is a GLP-1 receptor agonist that suppresses appetite through hypothalamic melanocortin circuits, slows gastric emptying, and enhances glucose-dependent insulin secretion. Cagrilintide is a long-acting amylin analogue that activates amylin receptors in the area postrema and hypothalamus, producing a satiety signal that is mechanistically distinct from GLP-1.

The hypothesised synergy is pathway-level rather than simply dose-additive. GLP-1 and amylin are both incretin-like hormones secreted from the gastrointestinal tract and pancreas in response to nutrient intake, but they signal through different receptor systems. GLP-1 acts through the GLP-1 receptor, a class B G-protein-coupled receptor that couples primarily to Gs and increases cAMP. Amylin acts through a receptor complex comprising the calcitonin receptor and receptor activity-modifying proteins (RAMPs), which couples to Gi/o and decreases cAMP. The two pathways converge on overlapping hypothalamic circuits but through different intracellular signalling mechanisms, making their combination pharmacologically interesting.

What the clinical literature says#

The REDEFINE-1 Phase 2b trial randomised participants with obesity to CagriSema, semaglutide alone, cagrilintide alone, or placebo for 68 weeks. The CagriSema arm achieved approximately 22.7% mean body-weight reduction, compared with approximately 16.9% on semaglutide alone and approximately 11.5% on cagrilintide alone. The combination was significantly superior to both monotherapies, with a safety profile that reflected the individual components: gastrointestinal events dominated, with higher rates of nausea, vomiting, and diarrhoea than semaglutide alone.

The REDEFINE-4 head-to-head Phase 3 trial compared CagriSema against tirzepatide in participants with obesity and established cardiovascular disease or chronic kidney disease. Results reported in April 2026 showed that CagriSema did not meet the non-inferiority margin for weight loss compared with tirzepatide. Eli Lilly's tirzepatide (Zepbound) produced superior weight reduction in this higher-risk population, complicating the narrative that CagriSema is categorically the strongest combination available. For researchers, the REDEFINE-4 result is a valuable reminder that combination superiority is population-specific and endpoint-dependent.

Research implications for Canadian labs#

For Canadian researchers sourcing semaglutide and cagrilintide as research-use-only materials, the clinical literature provides a mechanistic framework but not a direct protocol. The doses used in REDEFINE-1 (semaglutide 2.4 mg weekly plus cagrilintide 2.4 mg weekly) are pharmaceutical-grade formulations with bioequivalence data that do not transfer automatically to lyophilised research peptides. Any research protocol that attempts to model the CagriSema combination must independently verify peptide identity, concentration, stability, and dosing assumptions.

A defensible research design would include:

• Body weight and food intake as primary endpoints, measured daily or every other day.
• Continuous glucose monitoring or frequent oral glucose tolerance tests to assess glycaemic effects independent of weight change.
• Gastric emptying studies (scintigraphy or acetaminophen absorption) to isolate the gastrointestinal component from the central appetite component.
• Plasma GLP-1 and amylin-like immunoreactivity to confirm target engagement, though assay cross-reactivity with synthetic analogues must be validated.

The DAC vs no-DAC parallel#

Readers familiar with growth-hormone peptide stacks will recognise a structural parallel. In the GH literature, the key debate is whether a long-acting GHRH analogue (CJC-1295 with DAC) or a short-acting analogue (CJC-1295 without DAC) produces the more physiologically relevant signal. In the weight-loss literature, a similar question arises with semaglutide's C-18 fatty diacid chain, which produces a seven-day half-life, versus shorter-acting GLP-1 agonists such as liraglutide. Canadian researchers designing combination protocols should consider whether the long half-life of semaglutide and cagrilintide produces a sustained, non-pulsatile signal that may differ materially from the intermittent peptide exposure seen in physiological incretin secretion.

The tirzepatide + non-incretin adjuvant question#

Why tirzepatide is different from semaglutide#

Tirzepatide is not merely a stronger GLP-1 agonist. It is a dual GIP/GLP-1 receptor co-agonist with roughly balanced affinity for both receptors at therapeutic doses. The GIP arm adds mechanisms that are not present in semaglutide: enhanced lipid clearance, improved insulin sensitivity in adipose tissue, and potentially greater preservation of beta-cell function. The dual mechanism means that tirzepatide already captures much of the "combination" logic that motivates semaglutide-plus-cagrilintide research.

This has implications for stack design. Adding a third incretin-class peptide to tirzepatide—whether another GLP-1 agonist, a GLP-1/GIP dual agonist, or a gastric inhibitory polypeptide analogue—is unlikely to produce mechanistic novelty. The receptors are already occupied. Any additional effect would be pharmacokinetic (prolonging duration) rather than pharmacodynamic (activating a new pathway).

Tirzepatide plus AOD-9604: central appetite plus peripheral lipolysis#

A more defensible combination pairs tirzepatide with AOD-9604. The rationale is pathway orthogonality. Tirzepatide suppresses appetite centrally and slows gastrointestinal transit. AOD-9604 stimulates lipolysis peripherally through beta-3 adrenergic receptors in white adipose tissue. These are not the same pathway. They do not share a receptor. They do not compete for the same extracellular pool.

The hypothesised synergy is spatial: tirzepatide reduces energy intake, while AOD-9604 increases the mobilisation of stored fat to meet energy demands. In a model where caloric restriction is imposed, the combination might be expected to preserve lean mass better than caloric restriction alone by enhancing the availability of free fatty acids for oxidation. This hypothesis is theoretically plausible but not empirically validated in published trials. Canadian researchers interested in this combination should design protocols with endpoints that can distinguish central appetite effects from peripheral lipolytic effects:

• Body composition by DXA or MRI, with separate quantification of fat mass, lean mass, and visceral adipose tissue.
• Indirect calorimetry to measure resting energy expenditure, respiratory exchange ratio, and substrate utilisation.
• Plasma free fatty acids, glycerol, and beta-hydroxybutyrate as markers of lipolysis and ketogenesis.
• Food intake records or automated feeding monitors to isolate the appetite component.

Tirzepatide plus MOTS-c: incretin biology plus mitochondrial flux#

Another orthogonal pairing is tirzepatide with MOTS-c. Tirzepatide addresses the energy-intake side of the energy-balance equation. MOTS-c addresses the energy-expenditure and metabolic-flux side by activating AMPK, improving skeletal-muscle glucose uptake, and enhancing fatty-acid oxidation. The combination hypothesis is that central appetite suppression plus peripheral metabolic enhancement might produce greater net energy deficit than either compound alone, particularly in models where insulin resistance or impaired mitochondrial function limits the response to pure anorectics.

The evidence for this combination is sparse. A 2015 paper by Lee et al. in Cell Metabolism described MOTS-c as an exercise mimetic that improved insulin sensitivity and prevented obesity in high-fat-diet mice. A 2023 review in Nature Aging summarised the emerging literature on MOTS-c in metabolic disease, noting its effects on AMPK, mTOR, and NAD+ metabolism. Neither the original paper nor subsequent reviews examined MOTS-c in combination with GLP-1 or GIP receptor agonists. For Canadian researchers, this combination is genuinely exploratory.

Endpoint considerations for a tirzepatide-plus-MOTS-c study should include:

• Treadmill or wheel-running endurance to assess exercise capacity.
• Muscle glucose uptake measured by 2-deoxyglucose or positron-emission tomography.
• Mitochondrial respiration in isolated muscle fibres or permeabilised tissue.
• Liver triglyceride content and hepatic insulin sensitivity.
• Inflammatory markers (TNF-alpha, IL-6, MCP-1) because both compounds have been reported to influence immune metabolism.

The retatrutide context: triple agonism and stack redundancy#

Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The glucagon receptor arm adds hepatic glucose output, lipolysis, and energy expenditure through mechanisms that are distinct from GLP-1 and GIP. In the TRIUMPH-2 Phase 2b trial, retatrutide produced approximately 24.2% weight loss at 48 weeks, exceeding both semaglutide and tirzepatide at comparable time points.

From a stacking perspective, retatrutide presents a challenge: it already activates three major incretin/glucagon receptors. Adding semaglutide would mean more GLP-1 receptor agonism without adding a new receptor. Adding tirzepatide would mean more GLP-1 and GIP agonism. Adding cagrilintide would at least introduce amylin signalling, but the marginal gain is hypothesised rather than proven. For Canadian researchers, the most defensible stack involving retatrutide is retatrutide plus a non-incretin adjuvant such as AOD-9604 or MOTS-c, with a clear mechanistic justification and endpoints capable of detecting interaction effects.

AOD-9604 as a stack component: lipolysis without IGF-1#

Mechanism and evidence#

AOD-9604 is a synthetic analogue of the C-terminal fragment of human growth hormone (hGH 176-191). It was originally developed by Professor Frank Ng at Monash University and later investigated by Metabolic Pharmaceuticals for obesity treatment. Unlike full-length hGH, AOD-9604 does not bind to the growth hormone receptor and does not elevate circulating IGF-1. Its proposed mechanism is selective activation of beta-3 adrenergic receptors in adipose tissue, leading to increased lipolysis and reduced lipogenesis.

The clinical trial literature for AOD-9604 is limited. A Phase 2b trial in obese participants reported no significant difference in weight loss between AOD-9604 and placebo when administered orally. The failure was attributed to poor oral bioavailability rather than lack of mechanism, because the peptide is degraded by gastric proteases. Injectable formulations have been less extensively tested in humans, but the pre-clinical literature in rodents continues to support a lipolytic effect in white adipose tissue.

Stacking rationale: peripheral complement to central anorectics#

The value of AOD-9604 in a weight-loss stack is not as a standalone compound but as a peripheral adjuvant to central appetite suppressants. In a model where food intake is already reduced by a GLP-1 agonist, AOD-9604 might enhance the mobilisation of adipose triglycerides to fuel the energy deficit. This is analogous to the rationale for combining beta-3 agonists with caloric restriction in pharmaceutical development, though the clinical history of selective beta-3 agonists for obesity has been disappointing.

For Canadian researchers, the practical considerations for AOD-9604 include:

• HPLC purity of at least 98% with mass spectrometry confirming the expected molecular mass of approximately 1,817 Da.
• Lyophilised storage at -20°C in a desiccated environment; the peptide is susceptible to oxidation and moisture degradation.
• Subcutaneous administration in research models, because oral bioavailability is negligible.
• Endpoint panels that include adipose tissue histology (adipocyte size, macrophage infiltration), plasma lipids, and indirect calorimetry.

MOTS-c as a stack component: mitochondrial exercise mimetic#

Mechanism and evidence#

MOTS-c was discovered in 2015 as a mitochondrial-derived peptide encoded within the 12S rRNA gene. It is imported into the nucleus, where it regulates metabolic genes, and into the cytoplasm, where it activates AMPK. In high-fat-diet mice, MOTS-c prevented obesity, improved glucose tolerance, and enhanced exercise capacity. A randomised clinical trial (NCT07505745) is currently examining MOTS-c for insulin sensitivity in adults with prediabetes.

The mechanism is distinct from both incretin and lipolytic pathways. MOTS-c does not suppress appetite, slow gastric emptying, or stimulate beta-3 receptors. Instead, it improves the efficiency with which peripheral tissues—particularly skeletal muscle—utilise glucose and fatty acids. This makes it an interesting complement to central anorectics, because it addresses the energy-expenditure side of the energy-balance equation.

Stacking rationale: metabolic flux plus appetite suppression#

The combination of MOTS-c with a GLP-1 or dual incretin agonist asks a specific research question: does improving peripheral metabolic flux enhance the body-composition outcomes of caloric restriction? In a model where food intake is held constant, MOTS-c might increase fat oxidation and preserve lean mass. In a model where food intake is reduced by an anorectic, MOTS-c might prevent the adaptive thermogenesis and metabolic slowdown that often accompany weight loss.

This hypothesis is supported indirectly by the exercise literature: exercise increases MOTS-c levels in humans, and exercise combined with caloric restriction produces better body-composition outcomes than caloric restriction alone. Whether exogenous MOTS-c can substitute for exercise in this context is the open research question.

For Canadian researchers, sourcing MOTS-c requires the same COA-first standard as other peptides: lot-matched HPLC purity, mass spectrometry identity confirmation, sequence disclosure, sterility and endotoxin testing for injectable use, and clear research-use-only boundaries. The peptide is a 16-amino-acid sequence with a molecular mass of approximately 2,349 Da. Storage at -20°C in lyophilised form is standard. Reconstitution should use bacteriostatic water with documented pH and concentration.

Comparison table: weight-loss peptide stack combinations#

This table summarises the landscape but does not replace protocol design. The "research risk level" reflects epistemic risk—the probability of producing uninterpretable or misleading data—rather than clinical safety risk. The "evidence quality" column refers to published peer-reviewed data for the specific combination, not for the individual compounds.

What "synergy" means in weight-loss peptide research#

The word "synergy" is used casually in peptide forums but has a precise meaning in pharmacology. Two compounds are synergistic when their combined effect exceeds the sum of their individual effects at comparable concentrations. That definition requires three conditions:

1. Quantifiable effects: Each compound must produce a dose-dependent change in a specific endpoint (body weight, fat mass, food intake, glucose tolerance, etc.).
2. Additivity model: The researcher must define what "sum of individual effects" means mathematically. Common models include Bliss independence for effects on probabilities and Loewe additivity for dose-response curves.
3. Statistical test: The observed combination effect must be compared against the predicted additive effect with appropriate statistical power and correction for multiple comparisons.

Most anecdotal reports of "synergy" in weight-loss peptide stacks fail all three conditions. They describe subjective improvements in body composition, energy, or satiety without controlled dosing, without defined additivity models, and without statistical validation. For research purposes, synergy is a hypothesis to be tested, not a claim to be assumed.

In the specific context of weight-loss peptides, synergy testing is complicated by the slow, noisy nature of the endpoint. Body weight fluctuates with hydration, sodium intake, menstrual cycle, bowel contents, and measurement timing. A study that weighs subjects weekly may miss real effects or detect spurious ones. The minimum standard for meaningful weight-loss pharmacodynamic assessment is daily weighing under controlled conditions, with body composition by DXA or MRI at intervals of 4 weeks or more.

Study design principles for weight-loss peptide stack research#

Define the biological system first#

A common mistake in weight-loss research is to choose compounds before defining the model. The correct order is: identify the research question (e.g., "Does combining a GLP-1 agonist with an amylin analogue produce greater weight loss than either compound alone in a diet-induced obesity model?"), choose the endpoint that best captures that question (e.g., body composition by DXA), and then select the compounds that most directly address the relevant receptors.

If the research question is about metabolic outcomes, the endpoint might be glucose tolerance, insulin sensitivity, lipid oxidation, or hepatic steatosis. If the question is about gastrointestinal physiology, the endpoint might be gastric emptying time, intestinal transit, or nutrient absorption. Different questions require different compounds and different controls.

Use factorial designs for combination testing#

The minimum standard for combination research is a 2×2 factorial design: vehicle control, compound A alone, compound B alone, and A plus B. This design allows estimation of main effects, interaction effects, and deviations from additivity. For weight-loss peptide research, the design is complicated by the need for prolonged observation: body composition changes slowly, and acute measurements may not predict chronic outcomes.

A practical factorial design for semaglutide plus cagrilintide might include:

• Four treatment groups (vehicle, semaglutide alone, cagrilintide alone, combination).
• Daily body weight and food intake for 12 weeks.
• Body composition by DXA at baseline, 4 weeks, 8 weeks, and 12 weeks.
• Oral glucose tolerance test at baseline and 12 weeks.
• Gastric emptying study at 4 weeks.
• Plasma drug levels at steady state to confirm exposure.

Sample-size calculations should be powered for the interaction term, which typically requires larger N than main-effect testing. A common rule of thumb is that interaction detection requires roughly four times the sample size of main-effect detection for the same effect size and power.

Choose endpoints that match mechanism#

For GLP-1-plus-amylin studies, endpoints should include:

• Body weight, food intake, and body composition (fat mass, lean mass, visceral adipose tissue).
• Fasting glucose, insulin, HbA1c, and oral glucose tolerance.
• Gastric emptying time by scintigraphy or acetaminophen absorption.
• Plasma active GLP-1 and amylin-like immunoreactivity to confirm target engagement.

For GLP-1-plus-AOD-9604 studies, add:

• Plasma free fatty acids, glycerol, and beta-hydroxybutyrate.
• Indirect calorimetry (resting energy expenditure, respiratory exchange ratio).
• Adipose tissue histology (adipocyte size, lipid droplet morphology, macrophage infiltration).

For GLP-1-plus-MOTS-c studies, add:

• Treadmill or wheel-running endurance.
• Muscle glucose uptake by 2-deoxyglucose or PET.
• Mitochondrial respiration in permeabilised muscle fibres.
• Liver triglyceride content and hepatic insulin sensitivity markers.

Control for batch, storage, and analytical variation#

Weight-loss peptides are sensitive to heat, light, and oxidation. GLP-1 receptor agonists in particular are large, extensively modified peptides that degrade above 8°C. Batch-to-batch variation in purity, fill amount, and degradation products can easily confound small biological effects. The researcher should:

• Use a single lot for each peptide throughout the study, or stratify by lot.
• Store lyophilised peptides at -20°C or below, desiccated and protected from light.
• Reconstitute immediately before use; avoid freeze-thaw cycles.
• Verify identity and purity by independent third-party analysis if the supplier COA is more than six months old.
• Include vehicle controls matched for pH, osmolality, and excipient composition.

Document everything for reproducibility#

Weight-loss studies require thorough documentation. The research record should include:

• Supplier name, lot number, and date of receipt for each peptide.
• Storage conditions and temperature logs.
• Reconstitution date, solvent, pH, and concentration.
• Subject or animal strain, age, sex, diet composition, and housing conditions.
• Randomisation method, blinding protocol, and statistical analysis plan.
• Raw data files, not just summary statistics.

Analytical standards for combination sourcing#

Independent verification for each peptide#

When ordering multiple peptides for a weight-loss stack, each peptide should have its own lot-matched certificate of analysis. The COA should include:

• Sequence identity confirmation by mass spectrometry.
• Purity by HPLC with peak integration and area percent.
• Fill amount or concentration.
• Appearance and physical description.
• Sterility test result for injectable compounds.
• Endotoxin limit test result (ideally ≤2 EU/mL).
• Storage guidance and expiry or retest date.

Cold-chain integrity#

Canadian researchers ordering during warm months should confirm that the supplier uses insulated packaging with gel ice packs and temperature indicators. Domestic Canadian suppliers shipping within the country reduce the risk of customs delays and extended dwell times in uncontrolled facilities. For international orders, the risk of temperature excursions rises sharply, and researchers should consider express courier services with temperature-controlled containers.

Lynx Labs publishes batch-specific COAs for weight-loss peptides, including semaglutide, tirzepatide, retatrutide, cagrilintide, AOD-9604, and MOTS-c. Each listing includes direct COA download links with HPLC chromatograms and mass spectrometry data. For researchers unfamiliar with evaluating a peptide COA, Northern Compound's Canadian research peptide buyer guide provides a detailed walkthrough.

Red flags when evaluating weight-loss peptide suppliers#

The following patterns are meaningful warning signs:

• A COA without a batch or lot number cannot be linked to a specific production run.
• HPLC purity below 95% presented as acceptable for injectable compounds represents a material impurity burden.
• No mass spectrometry data for large modified peptides such as semaglutide, tirzepatide, or retatrutide means the supplier cannot confirm molecular identity.
• No cold-chain shipping documentation signals inadequate handling of temperature-sensitive products.
• No endotoxin test results for injectable compounds is a disqualifying gap.
• Therapeutic or personal-use language on a product page creates a compliance risk regardless of COA quality.
• Claims about "fat burning," "rapid weight loss," or "shredding" on a research-supply site indicate marketing language that blurs the research-use-only boundary.

Storage, handling, and stability#

Weight-loss peptide stacks span large modified incretin agonists, medium-sized lipolytic fragments, and small mitochondrial peptides. Storage demands differ.

Lyophilised semaglutide, tirzepatide, retatrutide, and cagrilintide should be stored at -20°C in a desiccated environment, protected from light. These peptides are large (semaglutide ~4,113 Da, tirzepatide ~4,816 Da, retatrutide ~5,600 Da), extensively modified with non-natural amino acids and fatty acid chains, and susceptible to oxidation and hydrolysis. Reconstitution should use bacteriostatic water or the vehicle specified in the protocol, with documented concentration, pH, and stability assumptions. Once reconstituted, GLP-1-class peptides should be used promptly or stored under conditions validated by stability data; many researchers discard reconstituted solutions after 7-14 days at 4°C unless specific stability data support longer storage.

AOD-9604 and MOTS-c are smaller peptides (AOD-9604 ~1,817 Da, MOTS-c ~2,349 Da) with less structural complexity than the incretin agonists. They are correspondingly more stable in lyophilised form but should still be stored at -20°C, desiccated and protected from light. Reconstitution follows the same principles as for the larger peptides: bacteriostatic water, documented concentration, and minimised freeze-thaw cycles.

For all materials, the research notebook should record date received, lot number, COA version, opening or reconstitution date, solvent used, storage temperature, and any deviations. A weak paper trail makes any result harder to interpret and any publication harder to defend.

Regulatory and compliance boundaries for Canadian researchers#

Health Canada does not authorise research-use-only peptides as medicines for weight management, obesity, or metabolic disease when sold through research-supply channels. The Food and Drugs Act distinguishes between approved therapeutic products and materials sold for legitimate non-clinical research. Canadian researchers should maintain that boundary in all documentation, protocol language, and publication.

Specific compliance cautions for the weight-loss peptide category include:

• Avoid dosing instructions for humans. Research protocols may specify administered quantities in animal models, but human dosing language crosses into therapeutic claim territory.
• Avoid before-and-after photographs, testimonials, or case reports that imply clinical efficacy.
• Avoid comparative language that positions research peptides as "better than" approved medicines unless the comparison is explicitly framed as a research hypothesis with appropriate controls.
• Preserve research-use-only language on all procurement records, storage labels, and experimental documentation.

The regulatory landscape is evolving. In 2026, both the FDA and Health Canada are paying increased attention to peptides marketed through compounding pharmacies and online research-supply channels. The 2026 FDA peptide crackdown has implications for Canadian researchers who source across the border. Domestic Canadian suppliers with transparent COAs, clear RUO language, and validated cold-chain logistics are a lower-compliance-risk option than international peers with ambiguous documentation.

Where the evidence is strong, and where it is thin#

The weight-loss peptide stack landscape can be divided into three tiers based on evidence quality.

Tier 1: Strong clinical combination data. Semaglutide plus cagrilintide (CagriSema) has Phase 2b and Phase 3 data showing superior weight loss to either monotherapy. The evidence is company-sponsored and subject to publication bias, but the magnitude and consistency of the effect are substantial enough to make CagriSema the most defensible combination in the current literature.

Tier 2: Strong individual data, no combination data. Tirzepatide, retatrutide, AOD-9604, and MOTS-c each have published individual data, but none have been tested in peer-reviewed factorial combination trials. The rationale for combining them is mechanistic inference, not empirical validation. This tier represents the frontier of honest research: plausible hypotheses that remain untested.

Tier 3: Limited or contested individual data. Some compounds marketed in weight-loss contexts have minimal published evidence. 5-Amino-1MQ, for example, is an NNMT inhibitor with animal-model data supporting NAD+ salvage and metabolic effects, but human clinical data are sparse. Researchers should treat such compounds as higher-risk and design protocols with extra attention to controls, replication, and endpoint specificity.

The strongest weight-loss stack research therefore combines mechanism, material identity, and endpoint discipline. A study that says "semaglutide plus cagrilintide reduced food intake and improved glucose tolerance in a defined diet-induced obesity model" is more useful than a claim that "this stack melts fat." Specificity protects both science and compliance.

FAQ: Weight-Loss Peptide Stacks in Canada#

Bottom line for Canadian researchers#

The weight-loss peptide stack landscape in Canada is driven by the incretin revolution but extends beyond it. Semaglutide plus cagrilintide has the strongest combination evidence. Tirzepatide and retatrutide are so mechanistically comprehensive that their stacking rationale shifts toward non-incretin adjuvants. AOD-9604 and MOTS-c offer peripheral mechanisms—lipolysis and mitochondrial flux—that are orthogonal to central appetite suppression and may justify combination research in carefully designed models.

Canadian researchers should prioritise three practical standards: verify material identity through lot-matched HPLC and mass spectrometry, preserve research-use-only boundaries in all documentation, and choose suppliers who provide transparent analytical data and conservative product claims over exciting marketing copy. The responsible path is to let the mechanism guide the choice, the documentation validate the material, and the evidence set the limits of the claim.

Nothing in this guide is medical advice, treatment guidance, dosing instruction, or a recommendation for personal use. All compounds discussed are research-use-only materials unless supplied through a lawful therapeutic pathway.